Hints and tips:
Related Special Reports
...systems”....
...Adalytics created a list of those hit, which includes dozens of leading brands such as JPMorgan Chase and Johnson & Johnson, as well the US Department of Health & Human Services....
...Paul Johnson, head of the Institute for Fiscal Studies, a think-tank, said Labour’s plans to increase taxes on private schools, individuals with non-domicile status and private equity bosses, would raise...
...In 2020, Pfizer spun off its generics business Upjohn, combining it with Mylan to form Viatris, while Johnson & Johnson, GSK, Pfizer and Novartis have all shed their consumer health businesses selling over-the-counter...
...“Neither Johnson & Johnson, nor any of its subsidiaries are in any financial distress....
...Johnson & Johnson reported a first-quarter loss as it booked a $6.9bn charge linked to its proposal to settle tens of thousands of legal claims related to allegations its talcum powder caused cancer....
...Late on Tuesday, an affiliate of Johnson & Johnson filed for bankruptcy protection....
...Johnson & Johnson’s newly formed consumer business has been targeted by claims that its talcum powder can cause cancer, days before it attempts to complete the largest US initial public offering in almost...
...& Johnson and the Koch Industries to use the bankruptcy system to manage personal injury claims....
...I think a lot of people were anticipating a V-shaped recovery . . . People are now waking up the realisation that volatility is going to be normal going forward.”...
...A US appeals court has dismissed a bankruptcy petition filed by a unit of Johnson & Johnson, upending the healthcare company’s attempt to resolve billions of dollars of legal claims from customers alleging...
...When Joaquin Duato delivered his first annual results as chief executive and chair of Johnson & Johnson last month, he enthused about being “excited for the future” of the company, which is poised to spin...
...A coalition of ethical investors have asked Johnson & Johnson, Merck, Pfizer, Eli Lilly, Gilead, Amgen, Regeneron, Bristol Myers Squibb and AbbVie to publish a report on the process they follow when applying...
...Horizon’s assets, which include treatments for chronic gout and neuromyelitis optica, a disease affecting the central nervous system, had also attracted interest from Johnson & Johnson and Sanofi....
...students and almost 3 per cent of middle school pupils used e-cigarettes last year, but the majority used a disposable device such as those made by Puff Bar and Stig rather than Juul’s cartridge-based system...
...Johnson & Johnson used the contentious “Texas two-step” bankruptcy strategy to halt 38,000 personal injury cases claiming its talc-based baby powder caused cancer....
...See our story below about efforts to get proper measurement systems in place for hydrogen investments....
...Sara has lots more advice about finding a free debt adviser and making a plan to tackle debts on our upcoming podcast episode. 5 Perform a pension health check The long-awaited arrival of the Pensions...
...A US judge has ruled that Johnson & Johnson can proceed with a controversial bankruptcy strategy to help it manage almost 40,000 legal claims that its baby talc causes cancer....
...Penny Heaton, global head of vaccines for Johnson & Johnson, said her team had begun preparing for the variant as soon as they had secured data....
...Medtronic, Johnson & Johnson and UK-based CMR Surgical are among the leading companies now vying for a share of the growing market and — in the process — making the technology more affordable....
...When cancer patient Shawn “Val” Johnson won a $27m personal injury award against Johnson & Johnson this month he was relieved that his family would not run short of cash when he dies....
...Understanding such complexities within organisations “might help us design less simplistic approaches to ethics — and social and environmental responsibility”, Alison Taylor at NYU Stern’s Ethical Systems...
...Health,” said Alex Gorsky, chair and chief executive....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
International Edition